McNaughton Wealth Management LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,818 shares of the company’s stock after buying an additional 68 shares during the quarter. McNaughton Wealth Management LLC’s holdings in Johnson & Johnson were worth $674,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently modified their holdings of the company. Wambolt & Associates LLC lifted its position in shares of Johnson & Johnson by 2.5% during the 4th quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after buying an additional 355 shares in the last quarter. Integral Investment Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.7% during the 4th quarter. Integral Investment Advisors Inc. now owns 11,270 shares of the company’s stock worth $1,991,000 after purchasing an additional 81 shares during the last quarter. Advisor OS LLC increased its stake in shares of Johnson & Johnson by 26.6% during the 4th quarter. Advisor OS LLC now owns 17,041 shares of the company’s stock worth $3,010,000 after purchasing an additional 3,581 shares during the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of Johnson & Johnson by 2.6% during the 4th quarter. Conestoga Capital Advisors LLC now owns 3,730 shares of the company’s stock worth $659,000 after purchasing an additional 95 shares during the last quarter. Finally, Bank of The West increased its stake in shares of Johnson & Johnson by 2.4% during the 4th quarter. Bank of The West now owns 31,575 shares of the company’s stock worth $5,578,000 after purchasing an additional 749 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.
Insider Buying and Selling at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.20% of the stock is currently owned by insiders.
Johnson & Johnson Trading Down 0.5 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.67 EPS. Research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s payout ratio is currently 94.56%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the stock. Raymond James decreased their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday. Atlantic Securities reduced their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Finally, UBS Group started coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective for the company. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $173.00.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
